Antibodies Take Center Stage in Alzheimer's

Q4 Biochemistry, Genetics and Molecular Biology

Genetic Engineering & Biotechnology News Pub Date : 2023-11-01 DOI:10.1089/gen.43.11.11

Uduak Thomas

引用次数: 0

Abstract

Genetic Engineering & Biotechnology NewsVol. 43, No. 11 Drug DiscoveryAntibodies Take Center Stage in Alzheimer'sAntibody-based treatments have transformed oncology, and they could do the same for neurodegenerative disorders like Alzheimer's diseaseUduak ThomasUduak ThomasSearch for more papers by this authorPublished Online:9 Nov 2023https://doi.org/10.1089/gen.43.11.11AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 43Issue 11Nov 2023 Information© 2023 by GEN PublishingTo cite this article:Uduak Thomas.Antibodies Take Center Stage in Alzheimer's.Genetic Engineering & Biotechnology News.Nov 2023.30-32, 34.http://doi.org/10.1089/gen.43.11.11Published in Volume: 43 Issue 11: November 9, 2023PDF download

查看原文本刊更多论文

抗体在阿尔茨海默氏症中占据中心位置

基因工程与生物技术新闻卷。药物发现抗体成为阿尔茨海默病的中心以抗体为基础的治疗已经改变了肿瘤学。他们可以做同样的神经退行性疾病，如阿尔茨海默病uduak ThomasUduak ThomasUduak thomas搜索作者的更多论文发表在线:2023年11月9日https://doi.org/10.1089/gen.43.11.11AboutSectionsView文章查看全文pdf /EPUB权限和引文spermissionsdownload CitationsTrack引文添加到收藏回到出版物ShareShare onFacebookTwitterLinked InRedditEmail查看文章figuresreferencesrelateddetails卷43Issue 11Nov 2023信息©2023 byGEN publishing引用本文:Uduak Thomas。抗体在阿尔茨海默氏症中占据中心位置基因工程与生物技术新闻。2023年11月30日- 32,34 .http://doi.org/10.1089/gen.43.11.11Published第43卷第11期2023年11月9日pdf下载

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Genetic Engineering & Biotechnology News 工程技术-生物工程与应用微生物

CiteScore

0.20

自引率

0.00%

发文量

210

审稿时长

3-6 weeks

期刊介绍： Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Launched in 1980, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment growth, and career opportunities. With nearly 40 years of publishing experience, GEN maintains unrivaled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry. Through its cornerstone Magazine, high-frequency newsletters, and dynamic suite of multimedia resources, GEN is the 360-degree resource that researchers and executives depend on for information that is pivotal for their organization’s success. GEN’s breadth of editorial coverage is unrivaled in the industry, providing exclusive coverage of the entire bioproduct lifecycle across five key pillars: Drug Discovery, Bioprocessing, OMICS, Translational Medicine, and Gene Editing.